Institutional Only|Drovix does not deal with individual investors and does not accept deposits or provide retail trading services.

Drovix.
Counterparty Concentration Risk: A 2026 Diligence Framework
Market Analysis

Counterparty Concentration Risk: A 2026 Diligence Framework

Diversifying across three execution counterparties is nominal diversification if all three run through the same prime broker, the same LP panel, and the same colocation building.

HomeResourcesInsights & News
22 May 2026Drovix Research Desk8 min

Operational diligence on a new counterparty asks the right questions about the counterparty itself. Credit diligence asks the right questions about the counterparty's balance sheet. Counterparty concentration diligence asks a different question: what does the desk's exposure to this counterparty look like in the moments when several of its counterparties are simultaneously stressed?

Counterparties are not independent. They share LPs, they share clearing relationships, they share funding facilities, they share data-centre footprints, they share regulatory exposure. The desk that diversifies across three nominally-distinct execution counterparties may, in stress, find that all three are running through the same prime broker or the same emergency facility, and that the diversification it bought was nominal.

This piece is a framework for diligence on counterparty concentration as a structural risk — distinct from credit risk on any single name. It applies to institutional desks selecting their execution-counterparty mix in 2026.

Classical marble columns in a banking hall — structural foundation matters
Classical marble columns in a banking hall — structural foundation matters

The five concentration dimensions to map

Counterparty concentration shows up in five distinct dimensions, each of which the desk should map across its counterparty mix.

The first dimension is LP overlap. If a desk's three execution counterparties all source ~40% of their top-of-book from the same three bank LPs, the desk's effective LP diversification is not three counterparties; it is essentially one panel of three banks accessed through three intermediaries. In a stress window where those three banks pull back simultaneously, the desk has no resilient pricing across any of its three nominal counterparties.

The second dimension is prime-broker overlap. Many institutional execution counterparties hold their inventory and post their margin through one of a small number of prime brokers. If two of a desk's execution counterparties run through the same PB, a PB-side event affects both simultaneously — the desk's exposure to that PB is double-counted.

The third dimension is clearing and settlement-corridor overlap. Counterparties that settle through the same correspondent bank in the same currency are subject to that correspondent's cut-off, liquidity and operational events. A correspondent-bank holiday or operational outage hits multiple counterparties in the same window.

The fourth dimension is data-centre and connectivity overlap. Counterparties whose matching engines run in the same colocation building can be affected by a single building-wide event — power, cooling, network transit, regulatory inspection. The desk's diversification across two counterparties in LD4 is operationally less robust than diversification across LD4 and FR2.

The fifth dimension is regulatory exposure. Counterparties licensed in the same jurisdiction are subject to the same regulator's decisions — capital rules, leverage caps, restricted-jurisdiction lists, periodic audits. Diversifying across jurisdictions reduces single-regulator risk but increases operational complexity.

The diligence questions, per dimension

For each of the five dimensions, the desk should ask the counterparty a specific question and require a specific level of disclosure.

On LP overlap: ask the counterparty to disclose its top-10 LPs by routed volume, broken out by asset class. Most institutional counterparties will not disclose individual LP names but will disclose enough about the panel composition (number of bank LPs, number of non-bank LPs, share of total volume routed to the top-3 LPs) that the desk can model overlap across counterparties at the structural level.

On prime-broker overlap: ask the counterparty to disclose its prime broker(s) for inventory and margin. PB identity is generally not confidential and is a hard requirement for diligence.

On settlement-corridor overlap: ask the counterparty for the correspondent banks it uses in each major currency. Settlement-corridor risk is operationally specific and frequently overlooked.

On data-centre overlap: ask the counterparty for the specific colocation buildings hosting its primary and disaster-recovery matching engines. "Equinix" is not a building; "Equinix LD4" is. The granularity matters.

On regulatory exposure: confirm the counterparty's primary and secondary regulator and any pending regulatory matters disclosed in its most recent compliance review.

What good diversification looks like

A desk that has executed the diligence above and arrived at a counterparty mix with low concentration on every dimension should expect to be using three or four counterparties, each with a distinct PB, materially non-overlapping LP panels, settlement through different correspondent groups, primary engines in different colocation buildings, and regulators in different jurisdictions.

This is harder than it sounds. The number of institutional execution counterparties in 2026 that satisfy all five dimensions, even within a single asset class, is small. Most institutional desks end up with one or two "primary" counterparties whose concentration profile is acceptable, plus one or two "backup" counterparties whose concentration overlaps materially with the primaries but whose value is operational redundancy in case of a primary-counterparty event.

Backup counterparties are still useful for that operational redundancy. They are not useful as structural diversification, and the desk should not treat them as such in its risk reporting.

An antique brass scale balance — structural balance across counterparties
An antique brass scale balance — structural balance across counterparties

Where Drovix sits in the framework

Drovix's institutional positioning is as one of the counterparties in a desk's diversified mix, not as the sole counterparty. The structural choice supports this: Drovix maintains a curated LP panel that is materially distinct from the panels operated by the largest US and European institutional brokers; its prime-broker and settlement-corridor relationships are documented and available to counterparties on diligence; its primary engines run in Equinix LD4 with disaster recovery in FR2 and active-active footprint into NY4; its regulator is the FSC of Mauritius, distinct from the regulators of the dominant US and European counterparties.

The structural distinctness is the product feature. A desk that uses Drovix as one of three counterparties — with the other two structured around different LP panels, different PBs, different colocations and different regulators — has materially lower concentration risk on every dimension than a desk that uses three counterparties that all run through the same Tier-1 US bank PB and the same handful of Tier-1 bank LPs.

Drovix publishes the diligence pack required for the framework above on request. The point is to make the structural concentration question answerable in a single meeting, with documented answers, rather than left to the desk's risk officer to inferred from public sources.

The relationship between margin-model pro-cyclicality and concentration in a stress window is in margin pro-cyclicality; the LP-panel side of concentration is in the capacity curve of aggregated liquidity.

Analyst Desk

Drovix Research Desk

Institutional Research

Drovix Research Desk publishes institutional-grade analysis covering macro events, cross-asset correlations, and execution insights for professional market participants.

Related Reads

Market Analysis

The Anatomy of an Effective Spread: A 2026 Microstructure Survey

Next Read

Market Analysis

Asymmetric Last Look: Where the Rejection Bias Hides in Plain Sight

Next Read

Market Analysis

The Half-Life of Information in FX Orders

Next Read

Back to Insights
Drovix.

Institutional-grade liquidity, connectivity, and analytics for professional market participants worldwide.

About

  • Why Drovix
  • Regulation
  • Technology
  • Contact
  • Insights
  • Execution Policy

Legal

  • Privacy
  • Terms and Agreements
  • Client Agreement
  • Risk Disclosure

Policies

  • AML/KYC Policy
  • Cookie Policy
  • Order Execution Policy
  • Complaints Handling
  • Reverse Solicitation
  • Site map

Risk Warning: Trading leveraged products such as Forex and CFDs carries a significant level of risk and may not be appropriate for all market participants. The value of derivative instruments can fluctuate rapidly, and losses may exceed initial margin. Institutional and professional clients should ensure they fully understand the risks associated with leveraged products before engaging in any transactions. Past performance is not indicative of future results. A significant proportion of professional client accounts incur losses when trading leveraged products. Prospective clients should ensure they have sufficient expertise and resources to bear the risks of leveraged trading. You should not commit capital that you cannot afford to lose.

Important — No Investor Compensation: Important: Client funds held with Drovix (MU) Ltd are not protected by any government deposit guarantee or investor compensation scheme. The Financial Services Commission (FSC) of Mauritius does not operate an investor compensation fund.

The information on this website is intended for institutional and professional clients only. It does not constitute investment advice, a solicitation, or a recommendation to enter into any transaction. Drovix does not provide services to retail clients.

Reverse Solicitation Notice: The information and services on this website are not directed at or intended for distribution to residents or nationals of any country or jurisdiction where such distribution or use would be contrary to local law or regulation. Institutional clients access Drovix (MU) Ltd services on their own initiative. It is the responsibility of each prospective institutional client to ensure compliance with the laws and regulations of their jurisdiction of incorporation or domicile.

This information is not intended for entities or persons in countries or jurisdictions under significant sanctions, including but not limited to Afghanistan, Barbados, Belarus, Burkina Faso, Cameroon, Central African Republic, Cuba, Democratic Republic of Congo, Haiti, Iran, Libya, Mali, Mozambique, Myanmar, Nicaragua, North Korea, Russia, Senegal, Sudan, Syria, Tanzania, Venezuela, Yemen, and Zimbabwe.

All information, products, and services offered on the Drovix website are not intended for entities or persons in Australia, Belgium, Canada, France, Japan, Malaysia, Poland, Ukraine, the United Kingdom, or the United States. The information on this website does not constitute investment advice or a recommendation or a solicitation to engage in any investment activity. Drovix services are available exclusively to eligible institutional and professional clients.

© 2026 Drovix (MU) Ltd. All rights reserved.

Drovix (MU) Ltd is authorised by the Financial Services Commission (FSC) in Mauritius under Investment Dealer (Full Service Dealer) excluding Underwriting licence No. GB21026813.

The company operates under www.drovix.com and is registered at C/o SALVUS (Mauritius) Ltd, Silver Bank Tower, Ground Floor, 18 Bank Street, Cybercity, Ebene 72201 Mauritius.